The improvement from baseline in the SGRQ score was @ points and @ points greater in the intravenous and subcutaneous mepolizumab groups , respectively , than in the placebo group ( minimal clinically important change , @ points ) , and the improvement in the ACQ-@ score was @ points and @ points greater in the two mepolizumab groups , respectively , than in the placebo group ( minimal clinically important change , @ points ) ( P < @ for all comparisons ) .